References
- 1. Arnold M, Karim-Kos HE, Coebergh JW, Byrnes G, Antilla A, Ferlay J, et al. (2015). Recent trends in incidence of five common cancers in 26 European countries since 1988: analysis of the European Cancer Observatory. Eur J Cancer 51(9):1164-87. doi: 10.1016/j.ejca.2013.09.002.
- 2. Hoffman RM, Meisner AL, Arap W, Barry M, Shah SK, Zeliadt SB, et al. (2016). Trends in United States Prostate Cancer Incidence Rates by Age and Stage, 1995-2012. Cancer Epidemiol Biomarkers Prev. 25(2):259-63. doi: 10.1158/1055-9965.EPI-15-0723.
- 3. Shao YH, Demissie K, Shih W, Mehta AR, Stein MN, Roberts CB, et al. (2009). Contemporary risk profile of prostate cancer in the United States. J Natl Cancer Inst. 101(18):1280-3. doi: 10.1093/jnci/djp262.
- 4. van Poppel H (2014). Locally advanced and high risk prostate cancer: The best indication for initial radical prostatectomy? Asian J Urol. 1(1):40-45. doi: 10.1016/j.ajur.2014.09.009.
- 5. Noone AM, Howlader N, Krapcho M, Miller D, Brest A, Yu M, et al. (eds) (2018). SEER Cancer Statistics Review, 1975-2015, National Cancer Institute. Bethesda, MD, https://seer.cancer.gov/csr/1975_2015/. Accessed April 30, 2018.
- 6. Institut za javno zdravlje Srbije „Dr Milan Jovanović Batut“. Incidencija i mortalitet od raka u centralnoj Srbiji, 1999-2008. [cited 2016 Apr 30]. Available from: http://www.batut.org.rs/.
- 7. Epstein JI, Allsbrook WC Jr, Amin MB, Egevad LL; ISUP Grading Committee (2005). The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma. Am J Surg Pathol. 29(9):1228-42. PubMed PMID: 16096414.
- 8. Brawley OW (2012). Trends in prostate cancer in the United States. J Natl Cancer Inst Monogr. 2012(45):152-6. doi: 10.1093/jncimonographs/lgs035.
- 9. Pepe P, Pennisi M (2015). Gleason score stratification according to age at diagnosis in 1028 men. Contemp Oncol (Pozn). 19(6):471-3. doi: 10.5114/wo.2015.56654.
- 10. Muralidhar V, Ziehr DR, Mahal BA, Chen YW, Nezolosky MD, Viswanathan VB, et al. (2015). Association Between Older Age and Increasing Gleason Score. Clin Genitourin Cancer. 13(6):525-30.e1-3. doi: 10.1016/j.clgc.2015.05.007.
- 11. Ji G, Huang C, Song G, Xiong G, Fang D, Wang H, et al. (2017). Are the Pathological Characteristics of Prostate Cancer More Aggressive or More Indolent Depending upon the Patient Age? Biomed Res Int. 2017:1438027. doi: 10.1155/2017/1438027.
- 12. Epstein JI, Walsh PC, Carter HB (2001). Dedifferentiation of prostate cancer grade with time in men followed expectantly for stage T1c disease. J Urol. 166(5):1688-91. PubMed PMID: 11586203.
- 13. Alibhai SM, Krahn MD, Fleshner NE, Cohen MM, Tomlinson GA, Naglie G (2004). The association between patient age and prostate cancer stage and grade at diagnosis. BJU Int. 94(3):303-6. PubMed PMID: 15291856.
- 14. Pierorazio PM, Walsh PC, Partin AW, Epstein JI (2013). Prognostic Gleason grade grouping: data based on the modified Gleason scoring system. BJU Int. 111:753–60. doi: 10.1111/j.1464-410X.2012.11611.x.
- 15. Epstein JI, Zelefsky MJ, Sjoberg DD, Nelson JB, Egevad L, Magi-Galluzzi C, et al. (2016). A Contemporary Prostate Cancer Grading System: A Validated Alternative to the Gleason Score. Eur Urol. 69(3):428-35. doi: 10.1016/j.eururo.2015.06.046.
- 16. Benson MC, Whang IS, Pantuck A, Ring K, Kaplan SA, Olsson CA, et al. (1992). Prostate specific antigen density: a means of distinguishing benign prostatic hypertrophy and prostate cancer. J Urol.147(3 Pt 2):815-6. PubMed PMID: 1371554.
- 17. Kulkarni GS, Al-Azab R, Lockwood G, Toi A, Evans A, Trachtenberg J, et al. (2006). Evidence for a biopsy derived grade artifact among larger prostate glands. J Urol. 175:505-9. PubMed PMID: 16406982.
- 18. Yilmaz H, Ustuner M, Ciftci S, Yavuz U, Ozkan TA, Dillioglugil O (2014). Prostate volume predicts high grade prostate cancer both in digital rectal examination negative (ct1c) and positive (≥ct2) patients. Int Braz J Urol. 40(5):613-9. doi: 10.1590/S1677-5538.
- 19. Ngo TC, Conti SL, Shinghal R, Presti JC Jr (2012). Prostate size does not predict high grade cancer. J Urol. 187:477-80. doi: 10.1016/j.juro.2011.10.042.
- 20. Stackhouse DA, Sun L, Schroeck FR, Jayachandran J, Caire AA, Acholo CO, et al. (2009). Factors predicting prostatic biopsy Gleason sum under grading. J Urol. 182(1):118-22. doi: 10.1016/j.juro.2009.02.127.
- 21. Mottet N, Bellmunt J, Bolla M, Briers E, Cumberbatch MG, De Santis M, et al. (2017). EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent. Eur Urol. 71(4):618-629. doi: 10.1016/j.eururo.2016.08.003.
- 22. Heidenreich A, Abrahamsson PA, Artibani W, Catto J, Montorsi F, Van Poppel H, et al. (2013). Early detection of prostate cancer: European Association of Urology recommendation. Eur Urol. 64(3):347-54. doi: 10.1016/j.eururo.2013.06.051.
- 23. Reese AC, Wessel SR, Fisher SG, Mydlo JH (2016). Evidence of prostate cancer “reverse stage migration” toward more advanced disease at diagnosis: Data from the Pennsylvania Cancer Registry. Urol Oncol. 34(8):335.e21-8. doi: 10.1016/j.urolonc.2016.03.014.
- 24. Schroder FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S, Nelen V, et al. ERSPC Investigators (2012). Prostate-cancer mortality at 11 years of follow-up. N Engl J Med. 366(11):981-90. doi: 10.1056/NEJMoa1113135.
- 25. Jani AB, Master VA, Rossi PJ, Liauw SL, Johnstone PA (2007). Grade migration in prostate cancer: an analysis using the Surveillance, Epidemiology, and End Results registry. Prostate Cancer Prostatic Dis. 10(4):347-51. PubMed PMID: 17505529.
- 26. Siddiqui MM, Rais-Bahrami S, Turkbey B, George AK, Rothwax J, Shakir N, et al. (2015). Comparison of MR/ultrasound fusion-guided biopsy with ultrasound-guided biopsy for the diagnosis of prostate cancer. JAMA. 313(4):390-7. doi: 10.1001/jama.2014.17942.